Evidence map›Paper›PMID 37742344›Full record

ArticleMedical physics2024

Multi-scale statistical deformation based co-registration of prostate MRI and post-surgical whole mount histopathology.

Lin Li, Rakesh Shiradkar, Noah Gottlieb, Christina Buzzy, Amogh Hiremath, Vidya Sankar Viswanathan, Gregory T MacLennan, Danly Omil Lima, Karishma Gupta, Daniel Lee Shen and 4 more

Abstract read
In one paragraph

Article in Medical physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lin LiDeptartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Rakesh ShiradkarWallace H Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA.
Noah GottliebDeptartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Christina BuzzyDeptartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Amogh HiremathDeptartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Vidya Sankar ViswanathanWallace H Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA.
Gregory T MacLennanDepartment of Pathology and Urology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Danly Omil LimaDepartment of Pathology and Urology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Karishma GuptaDepartment of Pathology and Urology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Daniel Lee ShenDepartment of Pathology and Urology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Sree Harsha TirumaniDepartment of Radiology, University Hospitals, Cleveland, Ohio, USA.
Cristina Magi-GalluzziDepartment of Pathology, University of Alabama at Birmingham, Alabama, USA.
Andrei PuryskoGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Anant MadabhushiWallace H Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA.

Funding

Pathology CoreU54CA254566 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2020 to 2024
$5.0M
Computer-Assisted Histologic Evaluation of Cardiac Allograft RejectionR01HL151277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MADABHUSHI, ANANT, MARGULIES, KENNETH BER · 2020 to 2023
$3.2M
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Prostate cancer risk stratification via computational 3D pathologyR01CA268207 · NCI · UNIVERSITY OF WASHINGTON · PI Jonathan T.C. Liu, Anant Madabhushi · 2022 to 2026
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
Prognostic and Predictive Digital Tissue Image Assay for Prostate CancerR01CA268287 · NCI · EMORY UNIVERSITY · PI GUPTA, SHILPA, LAL, PRITI · 2022 to 2025
$3.0M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
RADIOMIC APPROACHES TO IMPROVE TARGETING FOR ATRIAL FIBRILLATION CATHETER ABLATIONR01HL158071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BARNARD, JOHN, CHUNG, MINA KAY · 2021 to 2024
$2.9M
Novel Radiomics for Predicting Response to Immunotherapy for Lung CancerR01CA257612 · NCI · EMORY UNIVERSITY · PI Anant Madabhushi, Vamsidhar Velcheti · 2021 to 2026
$2.7M
An AI-enabled Digital Pathology Platform for Multi-Cancer Diagnosis, Prognosis and Prediction of Therapeutic BenefitU01CA269181 · NCI · EMORY UNIVERSITY · PI Anant Madabhushi, tanuja shet · 2022 to 2026
$2.5M
BLRD VA I01 BX004121BLRD VA IK6 BX006185CSRD VA I01 CX002622NCI NIH HHS 1U01CA239055-01NCI NIH HHS 1U01CA248226-01NCI NIH HHS 1U54CA254566-01NCI NIH HHS R01 CA202752NCI NIH HHS R01CA202752-01A1NCI NIH HHS R01 CA208236NCI NIH HHS R01CA208236-01A1NCI NIH HHS R01 CA216579NCI NIH HHS R01CA216579-01A1NCI NIH HHS R01 CA220581NCI NIH HHS R01CA220581-01A1NCI NIH HHS R01 CA249992NCI NIH HHS R01CA249992-01A1NCI NIH HHS R01 CA257612NCI NIH HHS R01CA257612-01A1NCI NIH HHS R01 CA268207NCI NIH HHS R01 CA268287NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U01 CA269181NCI NIH HHS U54 CA254566NCRR NIH HHS C06 RR012463NCRR NIH HHS C06 RR12463-01NHLBI NIH HHS R01 HL151277NHLBI NIH HHS R01 HL158071NIBIB NIH HHS 1R43EB028736-01NIBIB NIH HHS R43 EB028736
6 · The paper itself

Abstract

backgroundAccurate delineations of regions of interest (ROIs) on multi-parametric magnetic resonance imaging (mpMRI) are crucial for development of automated, machine learning-based prostate cancer (PCa) detection and segmentation models. However, manual ROI delineations are labor-intensive and susceptible to inter-reader variability. Histopathology images from radical prostatectomy (RP) represent the "gold standard" in terms of the delineation of disease extents, for example, PCa, prostatitis, and benign prostatic hyperplasia (BPH). Co-registering digitized histopathology images onto pre-operative mpMRI enables automated mapping of the ground truth disease extents onto mpMRI, thus enabling the development of machine learning tools for PCa detection and risk stratification. Still, MRI-histopathology co-registration is challenging due to various artifacts and large deformation between in vivo MRI and ex vivo whole-mount histopathology images (WMHs). Furthermore, the artifacts on WMHs, such as tissue loss, may introduce unrealistic deformation during co-registration. PURPOSE: This study presents a new registration pipeline, MSERgSDM, a multi-scale feature-based registration (MSERg) with a statistical deformation (SDM) constraint, which aims to improve accuracy of MRI-histopathology co-registration.

methodsIn this study, we collected 85 pairs of MRI and WMHs from 48 patients across three cohorts. Cohort 1 (D

resultsOur results suggest that MSERgSDM performed comparably to the ground truth (p > 0.05). Additionally, MSERgSDM (ROI Dice ratio = 0.61, landmark distance = 3.26 mm) exhibited significant improvement over MSERg (ROI Dice ratio = 0.59, landmark distance = 3.69 mm) and ProsRegNet (ROI Dice ratio = 0.56, landmark distance = 4.00 mm) in local alignment.

conclusionsThis study presents a novel registration method, MSERgSDM, for mapping ex vivo WMH onto in vivo prostate MRI. Our preliminary results demonstrate that MSERgSDM can serve as a valuable tool to map ground truth disease annotations from histopathology images onto MRI, thereby assisting in the development of machine learning models for PCa detection on MRI.

Indexed as

ProstateProstatic NeoplasmsHumansMagnetic Resonance ImagingMalePelvisProstatectomyhistologyMRIprostateregistration

Identifiers

PMID37742344
PMCPMC10960735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.